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A clinical approach to new-onset psychosis
associated with immune dysregulation: the
concept of autoimmune psychosis
Souhel Najjar1* , Johann Steiner2, Amanda Najjar3 and Karl Bechter4
Abstract: Growing data point to the overlap between psychosis and pathological processes associated with
immunological dysregulation as well as inflammation. Notably, the recent discovery of antibodies against synaptic
and neuronal cell membrane proteins such as anti-N-methyl-D-aspartate receptor provides more direct evidence
of the etiological connection between autoimmunity and subsequent hazard of psychosis. Here, we advocate the
use of term “autoimmune psychosis,” as this term suggests that autoimmune disorders can masquerade as drug-
resistant primary psychosis, and this subtype of psychosis has anatomical and immunological footprints in the
brain, despite the frequent absence of structural abnormalities on conventional brain MRI. Furthermore, this term
might serve as a reminder not to overlook appropriate neurological workup such as neuroimaging and EEG
testing, as well as CSF analysis, for cases with acute or subacute atypical onset of neuropsychiatric presentations
including those dominated by acute psychotic symptoms. We propose etiologically and serologically oriented
subclassification as well as multi-modal diagnostic approach to address some of the challenges inherent to early
diagnosis of patients presenting with atypical and refractory new-onset psychotic symptoms of autoimmune
origin. This is particularly relevant to the diagnosis of seronegative but probable autoimmune psychosis (SPAP)
that might masquerade as antipsychotic drug-resistant primary psychotic disorder. This distinction is
therapeutically important as autoimmune-related psychotic symptomatology can frequently respond well to
timely treatment with proper immune modulatory therapies.
Keywords: Autoimmune, Psychosis, NMDAR, Encephalitis, Neuroinflammation, Microglia, Neuronal, Synaptic,
Antibodies, Neuroimaging
Background
Human and animal data suggest that neuroinflammatory
and immunological abnormalities can contribute to the
neurobiology of primary psychotic disorders [1, 2]. Human
post-mortem brain, serological, cerebrospinal fluid (CSF),
neuroimaging, genetic, and epidemiological studies have
documented diverse inflammatory and immunological
abnormalities in a subgroup of patients diagnosed with
schizophrenia according to the currently established DSM/
ICD criteria [1–4]. Among the main inflammatory abnor-
malities are microglial activation and proliferation in brain
regions of functional relevance to psychosis (e.g., dorsolat-
eral prefrontal, superior temporal, and anterior cingulate
cortices), and upregulation of inflammatory mediators such
as pro-inflammatory cytokines and matrix metalloprotein-
ases [1–4]. Findings of post-mortem studies have not only
linked microglial activation to the neurobiology of psych-
osis but also to suicidal state [3, 4]. Recent meta-analysis of
post-mortem brains documented statistically significant
increase in microglial density and pro-inflammatory gene
expression, without significant alteration in the density of
other glial cells or anti-inflammatory gene expression in
schizophrenia compared with healthy subjects [5]. Studies
documenting elevated serum levels of beta2-microglobulin
in drug-naïve schizophrenia compared with healthy
cohorts [6], with further elevation of its levels following
treatment with antipsychotic medications, [7] suggest that
immune dysregulation may play a role in a subgroup of
these patients. Various CSF immunological and inflamma-
tory changes are also well documented in a subset of indi-
viduals with drug-resistant schizophrenia [8, 9]. These
changes include increased “CSF: serum albumin ratio”
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indicative of blood-CSF barrier hyperpermeability;
increased intrathecal synthesis of IgG, IgM, and/or IgA;
and presence of up to four IgG oligoclonal bands, mild
pleocytosis, elevated neopterin levels, and elevated cyto-
kines [8, 9]. These observations, together with documented
elevated levels of S100B protein, a marker of glial activation
and blood-brain barrier hyperpermeability, in the brain,
CSF as well as blood support the hypothesis that hyperper-
meability and/or disruption of blood-brain and blood-CSF
barriers may contribute to the neurobiology of psychosis,
in part via transendothelial inflammatory cell migration
and increased cross-talk between brain innate immunity
and peripheral adaptive immunity [1, 2, 8–10]. This is also
supported by the post-mortem ultrastructural findings of
inflammatory and degenerative changes affecting neurovas-
cular unit in schizophrenia [1, 2].
In addition, several epidemiological studies reported a
strong bidirectional relationship between autoimmune
disorders and psychosis [2, 11]. One study showed a
positive correlation between brain-reactive antibodies as-
sociated with autoimmune disorders and subsequent
hazard of psychosis [11], although the abundance of
brain-reactive IgG antibodies in the cortex of individuals
with schizophrenia was shown in another study to be
similar to that of healthy controls [12].
Moreover, the strong association between both early
infections and increased risk of developing psychosis in
the adult life [1, 11], as well as the significant increase in
serum titers of anti-CMV and anti-HSV1 and anti-HSV2
IgG antibodies in schizophrenia patients [13], provide in-
direct argument in support of immune involvement [11].
Collectively, the above data point to the overlap between
psychosis and pathological processes associated with im-
munological dysregulation as well as inflammation.
Antibodies against neurotransmitter receptors
and synaptic proteins in schizophrenia and new-
onset psychosis: the concept of autoimmune
psychosis
Early identification of antibodies targeting neurotransmitter
receptors, such as 5-hydroxytryptamine 1A receptor and
muscarinic cholinergic receptor 1, as well as dopamine-2
receptor, in individuals with schizophrenia suggests that
autoimmunity plays a role in a subgroup of these patients
[14–16]. Notably, the recent discovery of antibodies against
synaptic and neuronal cell membrane proteins such as anti-
N-methyl-D-aspartate receptor (NMDAR) and gamma-
aminobutyric acid beta receptor (GABAßR) provides more
direct evidence etiologically linking autoimmunity-related
dysregulation of glutamatergic and GABAergic neurotrans-
missions to subsequent hazard of psychosis [17–23]. One
meta-analysis showed that patient with psychiatric illnesses
such as schizophrenia and schizoaffective disorders are
about three times more likely to have NMDAR antibodies
(mostly of IgA or IgM type against GluN1 (NR1) subunit),
compared with healthy controls [24]. Similarly, other
studies reported higher, albeit variable, prevalence of IgG
antibodies targeting GluN1 subunit of NMDAR in the sera
of individuals with first-episode psychosis (ranging from 0
to 12%) [17–21, 25]. Furthermore, NMDAR antibody
immunofluorescence response in schizophrenia patients
with past catatonia is shown to be greater than that in
healthy controls [26]. Additional studies revealed higher
prevalence of other neuronal antibodies such as voltage-
gated potassium channel (VGKC)- complex antibodies in
patients with schizophrenia [27, 28]. On the contrary, the
findings from other studies provide counterargument to
the putative pathogenic significance of synaptic and neur-
onal antibodies in a subset of individuals with schizophre-
nia and new-onset psychosis. Several studies showed
comparable prevalence of antibodies targeting synaptic and
neuronal cell membrane protein among healthy and schizo-
phrenia cohorts [20, 29]. Another recent study showed that
the prevalence of these antibodies among individuals with
first-episode psychosis was low and comparable to that of
healthy controls [30]. The mixed results and the variability
in the estimates of synaptic and neuronal antibody sero-
positivity may in part be attributed to methodological het-
erogeneity (e.g., cell-based assay (CBA) using live as
opposed to fixed cells) that might have influenced the sensi-
tivity and specificity of immunostaining assays used across
these studies [24, 25].
The growing human and experimental data supporting
an association between autoimmunity and risk of develop-
ing psychosis have prompted some authors to use the term
“autoimmune psychosis” [17]. We advocate using the term
“autoimmune psychosis” for those autoimmune disorders
presenting primarily with atypical psychotic features mas-
querading as drug-resistant primary psychosis. This term
suggests that this subtype of psychosis has anatomical and
immunological footprints in the brain. It also serves as a
reminder not to overlook appropriate neurological workup,
(such as neuroimaging, EEG testing, and CSF investiga-
tion), but rather to apply it more broadly to formulate ac-
curate differential diagnostic considerations that entertain
underlying autoimmune process among other organic eti-
ologies. Examples of atypical psychotic presentations sug-
gestive of organic causes [31, 32] are (1) atypical age of
onset; (2) predominance of particular symptoms such as
confusion, disorientation, and language disintegration; (3)
catatonia, given its diverse etiology; (4) predominance of
visual or multi-modal hallucinations (visual and tactile); (5)
olfactory hallucinations suggestive of mesial temporal lobe
pathology; (6) predominance of specific delusions such as
those related to misidentifications (Capgras syndrome); (7)
antecedent or concurrent medical illness or systemic mani-
festations including significant weight loss; and (8) lack of
predisposing risk factors for primary psychosis such as a
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strong family history of schizophrenia, a premorbid schiz-
oid personality, or precipitating stress for mental disorder.
Multi-modal diagnostic approach
We recommend multi-modal diagnostic approach to
psychosis with suspected organic etiology, including im-
munological dysregulation, that greatly emphasize the im-
portance of thorough clinical assessment before
considering the ever-expanding options for costly ancillary
diagnostic testing, with the main objective of augmenting
timely recognition and treatment of this unique subgroup
of psychosis. The clinical evaluation includes obtaining de-
tailed medical and neurological history, performing thor-
ough general and neurological examinations, recognizing
atypical psychotic presentations, and identifying clinical ac-
companiments suggestive of immune dysregulation after
excluding other organic causes [17, 33, 34].
The clinical accompaniments [17, 33, 34] are (1) atypical
psychotic presentation [31, 32]; (2) neurological distur-
bances such as rapidly evolving encephalopathy, seizures
including faciobrachial dystonic seizures pathognomonic
for limbic encephalitis associated with leucine-rich-glioma
inactivated 1 (LGI1) antibody, abnormal movements, auto-
nomic instability, language disintegration, and reduced
level of consciousness; (3) antecedent systemic symptoms
or viral-like febrile illness suggestive of prodromal phase of
autoimmunity; (4) unexplained soft or overt findings on
neurological examination; and (5) strong personal or family
history of autoimmune disorders.
The ancillary diagnostic abnormalities suggestive of
underlying neuroimmune dysregulation [32–38] include
the followings: (1) elevated serum levels of antibodies tar-
geting synaptic and neuronal cell membrane proteins, or
biomarker characteristic for comorbid autoimmune disor-
ders such as systemic lupus erythematous and Hashimo-
to’s encephalopathy among many others; (2) CSF,
neuroimaging, and EEG abnormalities after excluding
other organic causes such as infectious etiologies: (a) CSF
abnormalities include antibodies targeting synaptic and
neuronal cell membrane proteins, lymphocytic pleocyto-
sis, oligoclonal bands, elevated IgG index, and elevated
neopterin level (a non-specific marker of T helper cell 1
activation-dependent immune response) [35]; (b) neuro-
imaging structural and functional abnormalities such as
unilateral or bilateral hippocampal MRI FLAIR/T2 signal
hyperintensities suggestive of autoimmune limbic enceph-
alitis [33], as well as hyper-, hypo-, or heterogeneous cere-
bral glucose metabolism on FDG- positron emission
tomography (PET) or altered cerebral blood flow on single
photon emission computed tomography (SPECT) [33, 36,
37]; we suspect that FDG hypermetabolism, as opposed to
hypometabolism, might be more indicative of inflamma-
tion after excluding alternative causes [38]; and (c) EEG
abnormalities such as epileptiform discharges, delta
brushes [33].
Autoimmune disorders presenting with new-onset
psychotic symptoms
We propose that psychotic presentations secondary to
immune dysfunction may be categorized into three
groups according to their specific etiology and serum
as well as CSF immunological profiles (Table 1). This
subclassification might facilitate early consideration of
these subgroups of autoimmune disorders in individ-
uals presenting primarily with atypical new-onset
psychosis of uncertain organic causes masquerading
as refractory primary psychosis.
1. Psychosis associated with autoantibodies targeting
well-characterized synaptic and neuronal cell surface
proteins [3–5]. Indeed, findings from several case re-
ports and clinical case series have linked autoanti-
bodies targeting NMDAR, α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor
(AMPAR), GABAßR and VGKC-protein complex, to
new-onset psychosis among other psychiatric distur-
bances (e.g., mania, anxiety, aggression, emotional la-
bility, and personality changes) as the dominant
presenting symptoms [17–23, 27, 38–42]. Although
the majority of these patients eventually exhibit a
wide constellation of neurological symptoms
throughout the course of the illness, isolated neuro-
psychiatric symptoms with dominant psychosis may
rarely remain the key symptoms; we suggest that the
latter pattern might constitute the presentation of
milder form or forme fruste of autoimmune enceph-
alitis. Thus, we recommend screening for these anti-
bodies in serum and CSF of individuals presenting
with new-onset atypical drug-refractory neuro-
psychiatric symptoms including new-onset psych-
osis, particularly in those exhibiting any of the above
highlighted clinical accompaniments. This is import-
ant, as structural neuroimaging abnormalities are
commonly not noted on conventional MRI in pa-
tients with autoimmune encephalitis associated with
these synaptic and neuronal surface autoantibodies
[43, 44]. Indeed, recent studies of anti-NMDAR en-
cephalitis showed that structural neuroimaging ab-
normalities are absent on initial presentation and
follow-up brain MRIs in about 89 and 79% of cases,
respectively, despite associated profound cognitive,
neurological, and neuropsychiatric disturbances [43].
Furthermore, identification of specific autoantibodies
does not only establish the diagnosis of autoimmune
psychosis, but also can clarify its subtype and guide
treatment.
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2. Psychosis associated with classical systemic
inflammatory and autoimmune disorders (e.g.,
neuropsychiatric systemic lupus erythematosus),
neuroinflammatory disorders (e.g., inflammatory
demyelinating disorders such as multiple sclerosis and
acute disseminated encephalomyelitis, and
neurosarcoidosis), Hashimoto’s encephalopathy, or
autoantibodies targeting intracellular antigens (i.e.,
glutamic acid decarboxylase and onconeuronal
antigens).
Neuropsychiatric systemic lupus erythematous
(NPSLE) occurs in 25 to 75% of SLE patients [1].
NPSLE includes cognitive deficit, headache,
psychiatric symptoms (e.g., anxiety, depression, and
psychosis), seizures, movement disorders, non-
specific demyelination, and cerebrovascular events
[32, 45, 46]. Psychiatric symptoms often occur
within the first 2 years of disease onset [1] and are
rarely limited to isolated psychosis [32]. The patho-
physiology of NPSLE is multifactorial and includes
inflammation-mediated microangiopathy and auto-
antibodies such as anti-GluN2 (NR2) subunits of
NMDAR, anti-ribosomal P (positive in 90% of
psychotic SLE patients), anti-endothelial cell, anti-
ganglioside, and anti-dsDNA, as well as anti-
phospholipid antibodies [1]. Other systemic
inflammatory disorders such as Sjögren’s syndrome,
vasculitis, and Behçet’s disease can also present with
a variety of neuropsychiatric features including
psychosis, in addition to a wide constellation of
neurological disturbances such as cognitive changes
[18]. Please refer to the comprehensive review
published on this topic [18].
Central nervous system (CNS) inflammatory
demyelinating disorders such as acute disseminated
encephalomyelitis [47] and multiple sclerosis [48]
can present with diverse psychotic features,
suggesting that these disorders may share some
common immune and inflammatory mechanisms
with primary psychotic disorders [49].
Neurosarcoidosis is another neuroinflammatory
disorder that can have neuropsychiatric
comorbidities with psychotic features. Indeed,
psychotic manifestations can be seen in up to 17% of
individuals with neurosarcoidosis [50].
Hashimoto’s encephalopathy is a relatively
uncommon steroid-responsive encephalopathy. It is
characterized by rapidly progressive non-specific
encephalopathy, seizures, myoclonus, stroke-like
episodes, and diverse neuropsychiatric features that
include mood disorders as well as psychosis [33].
This disorder is associated with thyroid antibodies,
which can are also present in about 13% of healthy
individuals [33]. Brain MRI and CSF investigations
may be normal or revealing non-specific abnormal-
ities [33].
Glutamic acid decarboxylase antibody seropositivity
has been associated with a variety of neurological
disorders including limbic encephalitis, which
typically present with neurological (e.g., cognitive,
short-term memory impairment, confusion, seizures)
and psychiatric symptoms (mood alteration, anxiety,
psychosis) [1, 33]. However, studies that are more
recent indicated that other concomitant antibodies,
such as those targeting GABAßR, are more likely to be
the culprit [51, 52].
Paraneoplastic limbic systems can also present with a
variety of neuropsychiatric including psychosis and
neurological symptoms such as seizures and cognitive
impairment [33]. Although onconeuronal antibodies
are associated with paraneoplastic CNS syndromes,
direct cytotoxic effects of T cell immunity appear to
be more etiologically relevant to pathophysiology of
paraneoplastic limbic encephalitis [53].
3. Seronegative but probable autoimmune psychosis
(SPAP). The evidence supporting the relevance of
SPAP as a distinct diagnostic category in clinical
practice is indirect, limited, and largely consists of
case reports that document responsiveness of
secondary psychosis to immune therapies despite
negative comprehensive serological assays for
systemic and central nervous system autoimmune
diseases, as well as lack of any other discernable
organic etiology [54, 55]. The molecular and cellular
changes of the pathoimmunological processes
underlying SPAP remain largely mysterious.
However, some of these cases may represent a
subgroup of the increasingly recognized spectrum of
seronegative autoimmune encephalitides [33, 50,
54–61] presenting primarily with acute or subacute
onset encephalopathy, short-term memory impair-
ment, and neuropsychiatric features with dominant
psychotic symptoms [54, 55]. Its etiological connec-
tion to the underlying immunological dysregulation
can be inferred only after excluding other alternative
organic causes such as infectious, toxic-metabolic,
substance abuse, neurodegenerative, or genetic
disorders. We suggest that seronegativity is likely
attributed to autoantibodies that either have not yet
been discovered or present exclusively in the CSF
that is often not analyzed in this subgroup of indi-
viduals; (I) many cases of paraneoplastic limbic
encephalitis previously characterized as seronegative
were subsequently found to be GABAßR antibody
seropositive [52], and (II) NMDAR antibodies were
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detected only in CSF of about 13% of individuals
with confirmed anti-NMDAR encephalitis through
research-based combined testing of immunohisto-
chemistry and CBAs [62]. The strong immunopre-
cipitation property of the brain can also result in
high binding of autoantibodies to their respective
receptors, thus limiting their free circulation and
detection in the serum and CSF [63]. Furthermore,
methodological heterogeneity might occasionally
contribute to false seronegativity; although the
current CBA testing using commercially available
kits is very specific, it appears to be less sensitive for
detecting antibodies targeting synaptic and neuronal
cell surface antigens (e.g., NMDAR, GABAßR,
AMPAR) in patients with suspected synaptic auto-
immune encephalitis, as compared to research-based
combined testing of both rodent brain immunohis-
tochemical staining as well as CBAs [64]. Indeed,
about 12% of all confirmed autoimmune encephalitis
cases were identified only after demonstrating
positive rodent brain reactivity on immunohisto-
chemical staining followed by research-based CBAs
[64]. Alternatively, CNS autoimmunity may be
mediated by not-yet-defined innate- or T cell
autoimmunity, instead of circulating autoantibodies
[1]. Thus, diagnosing SPAP requires high index of
clinical suspicion together with lower threshold for
referring patients with suspected SPAP for basic
diagnostic investigation such as neuroimaging, EEG
testing, and CSF analysis. However, given the rela-
tively low diagnostic yield of conventional brain MRI
[43, 44] and the limited use of CSF analysis, it is
conceivable that SPAP frequently escapes clinical de-
tection. Indeed, findings from recent studies asses-
sing the sensitivity of various diagnostic tests in
autoimmune encephalitis indicate that brain FDG-
PET offers a higher diagnostic yield, with cerebral
cortical hypometabolism being the most frequently
observed abnormality, compared with early EEG,
conventional brain MRI, and even CSF analysis [65].
A clinically meaningful response to immune therapy
trial, similar to the approach used in seronegative
rheumatologic disorders [66], might provide indirect
evidence of the underlying CNS autoimmunity, par-
ticularly when associated with restoration of func-
tional neuroimaging abnormalities of glucose
metabolism or blood flow following immune therapy
[36, 67, 68]. The yield of brain biopsy, similar to that
of autoimmune encephalitis, is likely low [41]. How-
ever, brain biopsy might be considered in carefully
selected cases of severe encephalopathy associated
with refractory psychotic features of undefined
organic causes to confirm their etiological connec-
tion to autoimmunity before initiating more
aggressive immunosuppressive therapies. Indeed, we
have reported cases and reviewed literature of brain
biopsy-proven seronegative autoimmune encephalitis
presenting with isolated neuropsychiatric disorders in-
cluding psychosis [54, 56]. Although the typical neu-
roinflammatory findings of perivascular and
parenchymal mononuclear inflammatory infiltrates
and/or microglial nodules are typically not etiologically
specific, but can, in the proper clinical context and after
excluding other organic etiologies such as infections,
provide indirect evidence of probable neuroimmune
process.
Conclusions and future directions
We believe that the suggested etiologically and serologic-
ally oriented subclassification as well as the multi-modal
diagnostic approach might address some of the challenges
inherent to early diagnosis of patients presenting with
atypical drug-resistant new-onset psychosis with sus-
pected link to immune dysregulation. This is particularly
relevant to the diagnosis of SPAP that might masquerade
as antipsychotic drug-resistant primary psychotic disorder.
This distinction is also therapeutically important as
autoimmune-related psychotic symptomatology can fre-
quently respond well to timely treatment with proper im-
mune modulatory therapies. However, building broader
consensus evidence-based guidelines highlighting cost-
efficient diagnostic workup and management of patients
presenting with unusual new-onset psychotic symptoms
with suspected autoimmune origin such as SPAP are war-
ranted. Large-sample randomized clinical trials investigat-
ing the prevalence of autoimmune psychosis among
individuals with new-onset psychosis are needed. The trial
designs need to incorporate more CSF studies and more
advanced multi-modal neuroimaging such as resting-state
functional brain MRI for elucidating potentially character-
istic neural network functional connectivity alterations
[44] as well as PET utilizing a novel translocator protein
(TSPO) radioligand for imaging microglia activation-
mediated neuroinflammation [69].
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